Lyra Therapeutics (LYRA) Accumulated Depreciation & Amortization (2021 - 2025)
Historic Accumulated Depreciation & Amortization for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $4.4 million.
- Lyra Therapeutics' Accumulated Depreciation & Amortization rose 785.65% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 785.65%. This contributed to the annual value of $4.1 million for FY2024, which is 11494.01% up from last year.
- Latest data reveals that Lyra Therapeutics reported Accumulated Depreciation & Amortization of $4.4 million as of Q3 2025, which was up 785.65% from $4.3 million recorded in Q2 2025.
- Lyra Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $4.7 million during Q3 2022, with a 5-year trough of $1.9 million in Q4 2023.
- Its 5-year average for Accumulated Depreciation & Amortization is $3.9 million, with a median of $4.1 million in 2024.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first tumbled by 5397.7% in 2023, then skyrocketed by 11494.01% in 2024.
- Lyra Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $3.9 million in 2021, then increased by 7.61% to $4.2 million in 2022, then crashed by 53.98% to $1.9 million in 2023, then skyrocketed by 114.94% to $4.1 million in 2024, then increased by 7.73% to $4.4 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $4.4 million for Q3 2025, versus $4.3 million for Q2 2025 and $4.3 million for Q1 2025.